Table 1.
Baseline characteristics of patients in the placebo and ICD group
| No diabetes | Diabetes | P values | |
|---|---|---|---|
| Patients, n (%) | 1136 (68) | 540 (32) | |
| Age, median [Q1–Q3] | 58 [50 68] | 61 [53, 68] | 0.0095 |
| Men, n (%) | 883 (78) | 411 (76) | 0.4606 |
| White, n (%) | 890 (78) | 393 (73) | 0.0218 |
| ICD implantation, n (%) | 570 (50) | 259 (48) | 0.3971 |
| NYHA class III, n (%) | 314 (28) | 202 (37) | 0.0001 |
| Ischemic heart failure etiology, n (%) | 551 (49) | 333 (62) | 0.0001 |
| Left ventricular ejection fraction, median [Q1–Q3] | 23.5 [19, 30] | 25 [20, 30] | 0.0074 |
| Systolic blood pressure, mmHg, median [Q1–Q3] | 117 [104, 130] | 120.0 [108.0, 135.0] | 0.0011 |
| Diastolic blood pressure, mmHg, median [Q1–Q3] | 70 [62, 80] | 70 [60, 80] | 0.3732 |
| Weight, Kg, median [Q1–Q3] | 84 [73, 98] | 89 [77, 104] | 0.0001 |
| Heart rate, beats/min, median [Q1–Q3] | 72 [64, 83] | 77 [68, 86] | 0.0001 |
| eGFR, mL/min/1.73 m2, median [Q1–Q3] | 71 [57, 85] | 68 [52, 82] | 0.0007 |
| Medical history, n (%) | |||
| Atrial fibrillation/flutter | 170 (15) | 88 (16) | 0.4803 |
| Hypertension | 564 (50) | 367 (68) | 0.0001 |
| Myocardial infarction | 478 (71) | 282 (76) | 0.0402 |
| Stroke | 64 (6) | 45 (8) | 0.0362 |
| Pulmonary disease | 213 (19) | 120 (22) | 0.0959 |
| Medicationa, n (%) | |||
| ACE inhibitor or ARB | 1093 (96) | 517 (96) | 0.641 |
| Β-Blocker | 788 (69) | 369 (68) | 0.6691 |
| Mineralocorticoid-receptor antagonist | 210 (19) | 107 (20) | 0.5162 |
| Diuretic | 923 (81) | 480 (89) | 0.0001 |
| Digoxin | 763 (67) | 378 (70) | 0.2447 |
| Insulin | 0 (0) | 198 (37) | – |
| Oral hypoglycemic agents | 0 (0) | 325 (60) | – |
Q-quartile, ICD implantable cardioverter defibrillator, ACE angiotensin-converting enzyme, ARB angiotensin-receptor blocker, eGFR estimated glomerular filtration rate
aAt baseline